University of Pittsburgh

Lori Ann Emert-Sedlak

Billy W Day

Thomas E Smithgall

Prema Chandrasekhar Iyer

Toshiaki Kodama

Weixiang Dai

Jielu Zhao

Ronald P Trible

Disclosed herein are embodiments of a compound capable of treating HIV. In particular disclosed embodiments, the compound is capable of inhibiting Nef, such as by acting as antagonists of HIV Nef function. Also disclosed are embodiments of a method of making the compound, embodiments of a method of using the compound, and embodiments of a method of identifying HIV Nef antagonists. The disclosed compound may be used alone or in combination with other pharmacologically active agents in order to promote reducing drug resistance and/or cumulative toxicity.

Compounds for treating HIV and methods for using the compounds

Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro.

Targeting an HIV-1 nef-host cell kinase complex

Growing community of inventors

Cranberry Township, PA, United States of America

Lori Ann Emert-Sedlak